148 related articles for article (PubMed ID: 36013156)
1. The Role of
Klimaitė R; Kazokaitė M; Kondrotienė A; Daukšienė D; Sabaliauskaitė R; Žukauskaitė K; Žilaitienė B; Jarmalaitė S; Daukša A
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013156
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.
Mohammadi-asl J; Larijani B; Khorgami Z; Tavangar SM; Haghpanah V; Kheirollahi M; Mehdipour P
Med Oncol; 2011 Dec; 28(4):1123-8. PubMed ID: 20535589
[TBL] [Abstract][Full Text] [Related]
4. Correlation of thyroid stimulating hormone receptor mRNA expression levels in peripheral blood with undesirable clinicopathological features in papillary thyroid carcinoma patients.
Liu R; Hao S; Zhang H; Ma J; Liu X; Xu J; Liu X; Ning J; Sun Y; Jiang L; Li G; Song X; Zheng H
Oncotarget; 2017 Sep; 8(43):74129-74138. PubMed ID: 29088773
[TBL] [Abstract][Full Text] [Related]
5. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis.
Qu M; Wan S; Ren B; Wu H; Liu L; Shen H
Endocrine; 2020 Sep; 69(3):508-515. PubMed ID: 32279226
[TBL] [Abstract][Full Text] [Related]
6. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material.
Kartal K; Onder S; Kosemehmetoglu K; Kilickap S; Tezel YG; Kaynaroglu V
BMC Cancer; 2015 Oct; 15():824. PubMed ID: 26519197
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors.
Wei F; Wu Y; Wang Z; Li Y; Wang J; Shao G; Yang Y; Shi B
Clin Endocrinol (Oxf); 2020 Aug; 93(2):187-195. PubMed ID: 32286703
[TBL] [Abstract][Full Text] [Related]
8. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.
Schagdarsurengin U; Gimm O; Dralle H; Hoang-Vu C; Dammann R
Thyroid; 2006 Jul; 16(7):633-42. PubMed ID: 16889486
[TBL] [Abstract][Full Text] [Related]
9. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.
Aliyev A; Gupta M; Nasr C; Hatipoglu B; Milas M; Siperstein A; Berber E
Endocr Pract; 2015 Jul; 21(7):777-81. PubMed ID: 25786552
[TBL] [Abstract][Full Text] [Related]
10. Organochlorine pesticides and epigenetic alterations in thyroid tumors.
Salimi F; Asadikaram G; Ashrafi MR; Zeynali Nejad H; Abolhassani M; Abbasi-Jorjandi M; Sanjari M
Front Endocrinol (Lausanne); 2023; 14():1130794. PubMed ID: 37560303
[TBL] [Abstract][Full Text] [Related]
11. Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.
Liu TR; Su X; Qiu WS; Chen WC; Men QQ; Zou L; Li ZQ; Fu XY; Yang AK
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3582-91. PubMed ID: 27649658
[TBL] [Abstract][Full Text] [Related]
12. TSHR rs2288496 associated with thyroid hormone and predict the occurrence of lymph node metastasis of papillary thyroid cancer.
Su X; Lin LW; Weng JL; Chen SW; Yang XH; Zhou DL; Long YK; Shao Q; Ye ZL; Peng JL; Deng L; He CY; Yang AK
Cancer Biomark; 2019; 26(4):461-470. PubMed ID: 31658048
[TBL] [Abstract][Full Text] [Related]
13. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
Nakamura N; Carney JA; Jin L; Kajita S; Pallares J; Zhang H; Qian X; Sebo TJ; Erickson LA; Lloyd RV
Lab Invest; 2005 Sep; 85(9):1065-75. PubMed ID: 15980887
[TBL] [Abstract][Full Text] [Related]
14. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies.
Zhang B; Liu S; Zhang Z; Wei J; Qu Y; Wu K; Yang Q; Hou P; Shi B
Diagn Pathol; 2014 Mar; 9():45. PubMed ID: 24588959
[TBL] [Abstract][Full Text] [Related]
16. Methylation markers differentiate thyroid cancer from benign nodules.
Stephen JK; Chen KM; Merritt J; Chitale D; Divine G; Worsham MJ
J Endocrinol Invest; 2018 Feb; 41(2):163-170. PubMed ID: 28612287
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
18. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
20. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
